nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—lung cancer—colon cancer	0.502	1	CtDrD
Crizotinib—SRC—colon cancer	0.217	0.83	CbGaD
Crizotinib—ABCB1—colon cancer	0.0444	0.17	CbGaD
Crizotinib—Localised oedema—Capecitabine—colon cancer	0.00112	0.0242	CcSEcCtD
Crizotinib—Gastrointestinal perforation—Capecitabine—colon cancer	0.00108	0.0235	CcSEcCtD
Crizotinib—Peripheral sensory neuropathy—Capecitabine—colon cancer	0.000988	0.0214	CcSEcCtD
Crizotinib—Dysaesthesia—Fluorouracil—colon cancer	0.000934	0.0203	CcSEcCtD
Crizotinib—Polyneuropathy—Capecitabine—colon cancer	0.000866	0.0188	CcSEcCtD
Crizotinib—Lymphopenia—Irinotecan—colon cancer	0.000824	0.0179	CcSEcCtD
Crizotinib—IGF1R—Topotecan—Irinotecan—colon cancer	0.000776	0.314	CbGdCrCtD
Crizotinib—Balance disorder—Fluorouracil—colon cancer	0.000739	0.016	CcSEcCtD
Crizotinib—Febrile neutropenia—Vincristine—colon cancer	0.00072	0.0156	CcSEcCtD
Crizotinib—Febrile neutropenia—Irinotecan—colon cancer	0.000701	0.0152	CcSEcCtD
Crizotinib—Febrile neutropenia—Fluorouracil—colon cancer	0.000672	0.0146	CcSEcCtD
Crizotinib—Dysaesthesia—Capecitabine—colon cancer	0.000653	0.0142	CcSEcCtD
Crizotinib—CDK7—Topotecan—Irinotecan—colon cancer	0.000626	0.253	CbGdCrCtD
Crizotinib—Disorder sight—Capecitabine—colon cancer	0.000593	0.0129	CcSEcCtD
Crizotinib—Lymphopenia—Capecitabine—colon cancer	0.000552	0.012	CcSEcCtD
Crizotinib—Balance disorder—Capecitabine—colon cancer	0.000516	0.0112	CcSEcCtD
Crizotinib—Visual acuity reduced—Capecitabine—colon cancer	0.000475	0.0103	CcSEcCtD
Crizotinib—Febrile neutropenia—Capecitabine—colon cancer	0.000469	0.0102	CcSEcCtD
Crizotinib—Gait disturbance—Vincristine—colon cancer	0.000444	0.00963	CcSEcCtD
Crizotinib—Respiratory failure—Vincristine—colon cancer	0.000441	0.00957	CcSEcCtD
Crizotinib—Gait disturbance—Irinotecan—colon cancer	0.000432	0.00938	CcSEcCtD
Crizotinib—Pulmonary embolism—Irinotecan—colon cancer	0.000422	0.00915	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Irinotecan—colon cancer	0.000422	0.00915	CcSEcCtD
Crizotinib—Haemoglobin decreased—Capecitabine—colon cancer	0.00041	0.0089	CcSEcCtD
Crizotinib—PLK4—Topotecan—Irinotecan—colon cancer	0.000408	0.165	CbGdCrCtD
Crizotinib—Neuropathy—Vincristine—colon cancer	0.000407	0.00882	CcSEcCtD
Crizotinib—Neuralgia—Capecitabine—colon cancer	0.000406	0.00882	CcSEcCtD
Crizotinib—Photophobia—Fluorouracil—colon cancer	0.000379	0.00823	CcSEcCtD
Crizotinib—Sepsis—Irinotecan—colon cancer	0.000366	0.00794	CcSEcCtD
Crizotinib—Hepatotoxicity—Capecitabine—colon cancer	0.000366	0.00793	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Irinotecan—colon cancer	0.000352	0.00764	CcSEcCtD
Crizotinib—Sepsis—Fluorouracil—colon cancer	0.000351	0.00761	CcSEcCtD
Crizotinib—Hepatic failure—Vincristine—colon cancer	0.00035	0.00759	CcSEcCtD
Crizotinib—Febrile neutropenia—Methotrexate—colon cancer	0.000349	0.00758	CcSEcCtD
Crizotinib—ABL1—Topotecan—Irinotecan—colon cancer	0.000343	0.139	CbGdCrCtD
Crizotinib—Visual disturbance—Irinotecan—colon cancer	0.000323	0.00701	CcSEcCtD
Crizotinib—AURKA—Topotecan—Irinotecan—colon cancer	0.000319	0.129	CbGdCrCtD
Crizotinib—Burning sensation—Methotrexate—colon cancer	0.000303	0.00656	CcSEcCtD
Crizotinib—Interstitial lung disease—Methotrexate—colon cancer	0.000297	0.00644	CcSEcCtD
Crizotinib—Gait disturbance—Capecitabine—colon cancer	0.000289	0.00628	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Vincristine—colon cancer	0.000283	0.00614	CcSEcCtD
Crizotinib—Pulmonary embolism—Capecitabine—colon cancer	0.000282	0.00613	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Capecitabine—colon cancer	0.000282	0.00613	CcSEcCtD
Crizotinib—Hypokalaemia—Irinotecan—colon cancer	0.000279	0.00605	CcSEcCtD
Crizotinib—Muscular weakness—Vincristine—colon cancer	0.000277	0.00602	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Irinotecan—colon cancer	0.000276	0.00598	CcSEcCtD
Crizotinib—Hepatotoxicity—Methotrexate—colon cancer	0.000272	0.00591	CcSEcCtD
Crizotinib—Fluid retention—Capecitabine—colon cancer	0.000268	0.00582	CcSEcCtD
Crizotinib—Abscess—Methotrexate—colon cancer	0.000266	0.00576	CcSEcCtD
Crizotinib—Neuropathy—Capecitabine—colon cancer	0.000265	0.00575	CcSEcCtD
Crizotinib—Muscular weakness—Fluorouracil—colon cancer	0.000259	0.00561	CcSEcCtD
Crizotinib—Neutropenia—Vincristine—colon cancer	0.000254	0.00551	CcSEcCtD
Crizotinib—Neutropenia—Irinotecan—colon cancer	0.000247	0.00537	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Irinotecan—colon cancer	0.000246	0.00534	CcSEcCtD
Crizotinib—Weight decreased—Vincristine—colon cancer	0.000246	0.00533	CcSEcCtD
Crizotinib—Sepsis—Capecitabine—colon cancer	0.000245	0.00532	CcSEcCtD
Crizotinib—Pneumonia—Vincristine—colon cancer	0.000244	0.00529	CcSEcCtD
Crizotinib—Weight decreased—Irinotecan—colon cancer	0.000239	0.0052	CcSEcCtD
Crizotinib—Neuropathy peripheral—Vincristine—colon cancer	0.000238	0.00515	CcSEcCtD
Crizotinib—Pneumonia—Irinotecan—colon cancer	0.000237	0.00515	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Capecitabine—colon cancer	0.000236	0.00511	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Fluorouracil—colon cancer	0.000236	0.00511	CcSEcCtD
Crizotinib—Hepatic function abnormal—Capecitabine—colon cancer	0.000235	0.00509	CcSEcCtD
Crizotinib—Hepatic failure—Capecitabine—colon cancer	0.000228	0.00495	CcSEcCtD
Crizotinib—Pneumonia—Fluorouracil—colon cancer	0.000227	0.00493	CcSEcCtD
Crizotinib—Infestation NOS—Fluorouracil—colon cancer	0.000226	0.0049	CcSEcCtD
Crizotinib—Infestation—Fluorouracil—colon cancer	0.000226	0.0049	CcSEcCtD
Crizotinib—MAP4K1—vagina—colon cancer	0.000223	0.00293	CbGeAlD
Crizotinib—TYK2—renal system—colon cancer	0.000223	0.00292	CbGeAlD
Crizotinib—FLT3—lymphoid tissue—colon cancer	0.000222	0.00291	CbGeAlD
Crizotinib—AXL—smooth muscle tissue—colon cancer	0.000222	0.00291	CbGeAlD
Crizotinib—Neuropathy peripheral—Fluorouracil—colon cancer	0.000222	0.00481	CcSEcCtD
Crizotinib—EPHB4—epithelium—colon cancer	0.00022	0.00289	CbGeAlD
Crizotinib—IGF1R—vagina—colon cancer	0.000219	0.00287	CbGeAlD
Crizotinib—JAK2—epithelium—colon cancer	0.000218	0.00287	CbGeAlD
Crizotinib—ACVR1B—liver—colon cancer	0.000217	0.00285	CbGeAlD
Crizotinib—PRKD1—lymph node—colon cancer	0.000217	0.00284	CbGeAlD
Crizotinib—AURKA—bone marrow—colon cancer	0.000216	0.00284	CbGeAlD
Crizotinib—Hypoaesthesia—Vincristine—colon cancer	0.000216	0.0047	CcSEcCtD
Crizotinib—EPHA2—epithelium—colon cancer	0.000216	0.00283	CbGeAlD
Crizotinib—MAP4K2—vagina—colon cancer	0.000216	0.00283	CbGeAlD
Crizotinib—Bradycardia—Irinotecan—colon cancer	0.000216	0.00468	CcSEcCtD
Crizotinib—RPS6KB1—renal system—colon cancer	0.000216	0.00283	CbGeAlD
Crizotinib—Urinary tract disorder—Vincristine—colon cancer	0.000215	0.00466	CcSEcCtD
Crizotinib—Respiratory failure—Methotrexate—colon cancer	0.000214	0.00464	CcSEcCtD
Crizotinib—LIMK1—lymph node—colon cancer	0.000214	0.00281	CbGeAlD
Crizotinib—Urethral disorder—Vincristine—colon cancer	0.000213	0.00463	CcSEcCtD
Crizotinib—STK3—vagina—colon cancer	0.000213	0.00279	CbGeAlD
Crizotinib—EPHB4—smooth muscle tissue—colon cancer	0.000212	0.00278	CbGeAlD
Crizotinib—TEK—epithelium—colon cancer	0.00021	0.00276	CbGeAlD
Crizotinib—JAK2—smooth muscle tissue—colon cancer	0.00021	0.00276	CbGeAlD
Crizotinib—Pulmonary embolism—Methotrexate—colon cancer	0.00021	0.00456	CcSEcCtD
Crizotinib—MERTK—bone marrow—colon cancer	0.000209	0.00274	CbGeAlD
Crizotinib—PRKD3—lymph node—colon cancer	0.000208	0.00273	CbGeAlD
Crizotinib—AURKA—vagina—colon cancer	0.000207	0.00272	CbGeAlD
Crizotinib—CSF1R—embryo—colon cancer	0.000206	0.0027	CbGeAlD
Crizotinib—TESK1—vagina—colon cancer	0.000206	0.0027	CbGeAlD
Crizotinib—Diplopia—Capecitabine—colon cancer	0.000205	0.00445	CcSEcCtD
Crizotinib—Visual impairment—Irinotecan—colon cancer	0.000204	0.00443	CcSEcCtD
Crizotinib—EPHB4—renal system—colon cancer	0.000204	0.00268	CbGeAlD
Crizotinib—NUAK2—bone marrow—colon cancer	0.000204	0.00267	CbGeAlD
Crizotinib—STK4—liver—colon cancer	0.000203	0.00267	CbGeAlD
Crizotinib—DSTYK—lymph node—colon cancer	0.000203	0.00267	CbGeAlD
Crizotinib—MAP4K5—smooth muscle tissue—colon cancer	0.000203	0.00266	CbGeAlD
Crizotinib—TEK—smooth muscle tissue—colon cancer	0.000203	0.00266	CbGeAlD
Crizotinib—JAK2—renal system—colon cancer	0.000203	0.00266	CbGeAlD
Crizotinib—PTK2B—lymphoid tissue—colon cancer	0.000202	0.00265	CbGeAlD
Crizotinib—ACVR1—bone marrow—colon cancer	0.000202	0.00265	CbGeAlD
Crizotinib—FLT3—bone marrow—colon cancer	0.000202	0.00265	CbGeAlD
Crizotinib—Cardiac disorder—Vincristine—colon cancer	0.000202	0.00438	CcSEcCtD
Crizotinib—Hypoaesthesia—Fluorouracil—colon cancer	0.000202	0.00438	CcSEcCtD
Crizotinib—BLK—lymph node—colon cancer	0.000201	0.00264	CbGeAlD
Crizotinib—MERTK—vagina—colon cancer	0.0002	0.00263	CbGeAlD
Crizotinib—PTK2B—digestive system—colon cancer	0.0002	0.00262	CbGeAlD
Crizotinib—LTK—lymph node—colon cancer	0.000199	0.00261	CbGeAlD
Crizotinib—CASK—lymph node—colon cancer	0.000199	0.00261	CbGeAlD
Crizotinib—RIPK2—digestive system—colon cancer	0.000198	0.0026	CbGeAlD
Crizotinib—Face oedema—Capecitabine—colon cancer	0.000198	0.00429	CcSEcCtD
Crizotinib—Cardiac disorder—Irinotecan—colon cancer	0.000197	0.00427	CcSEcCtD
Crizotinib—Mediastinal disorder—Vincristine—colon cancer	0.000196	0.00425	CcSEcCtD
Crizotinib—LIMK2—vagina—colon cancer	0.000196	0.00257	CbGeAlD
Crizotinib—TEK—renal system—colon cancer	0.000195	0.00256	CbGeAlD
Crizotinib—NUAK2—vagina—colon cancer	0.000195	0.00256	CbGeAlD
Crizotinib—MAP3K12—vagina—colon cancer	0.000194	0.00254	CbGeAlD
Crizotinib—ACVR1—vagina—colon cancer	0.000194	0.00254	CbGeAlD
Crizotinib—MAPK7—lymph node—colon cancer	0.000192	0.00253	CbGeAlD
Crizotinib—TXK—lymph node—colon cancer	0.000192	0.00253	CbGeAlD
Crizotinib—FER—liver—colon cancer	0.000192	0.00252	CbGeAlD
Crizotinib—LYN—liver—colon cancer	0.000191	0.00251	CbGeAlD
Crizotinib—Mediastinal disorder—Irinotecan—colon cancer	0.000191	0.00414	CcSEcCtD
Crizotinib—BMP2K—bone marrow—colon cancer	0.000191	0.0025	CbGeAlD
Crizotinib—FES—lymph node—colon cancer	0.00019	0.0025	CbGeAlD
Crizotinib—TNK1—liver—colon cancer	0.00019	0.0025	CbGeAlD
Crizotinib—MAP3K2—lymphoid tissue—colon cancer	0.00019	0.0025	CbGeAlD
Crizotinib—STK35—vagina—colon cancer	0.00019	0.00249	CbGeAlD
Crizotinib—Arrhythmia—Irinotecan—colon cancer	0.000189	0.00411	CcSEcCtD
Crizotinib—YES1—smooth muscle tissue—colon cancer	0.000187	0.00246	CbGeAlD
Crizotinib—SRC—epithelium—colon cancer	0.000187	0.00246	CbGeAlD
Crizotinib—Hypokalaemia—Capecitabine—colon cancer	0.000187	0.00405	CcSEcCtD
Crizotinib—PTK2—lymphoid tissue—colon cancer	0.000186	0.00244	CbGeAlD
Crizotinib—TBK1—lymphoid tissue—colon cancer	0.000186	0.00244	CbGeAlD
Crizotinib—TYK2—lymphoid tissue—colon cancer	0.000185	0.00243	CbGeAlD
Crizotinib—ABL2—vagina—colon cancer	0.000185	0.00243	CbGeAlD
Crizotinib—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.000185	0.004	CcSEcCtD
Crizotinib—TNK2—liver—colon cancer	0.000185	0.00242	CbGeAlD
Crizotinib—IGF1R—liver—colon cancer	0.000185	0.00242	CbGeAlD
Crizotinib—PTK2B—bone marrow—colon cancer	0.000184	0.00242	CbGeAlD
Crizotinib—TBK1—digestive system—colon cancer	0.000184	0.00241	CbGeAlD
Crizotinib—PTK2—digestive system—colon cancer	0.000184	0.00241	CbGeAlD
Crizotinib—TYK2—digestive system—colon cancer	0.000183	0.0024	CbGeAlD
Crizotinib—BMP2K—vagina—colon cancer	0.000183	0.0024	CbGeAlD
Crizotinib—RIPK2—bone marrow—colon cancer	0.000183	0.0024	CbGeAlD
Crizotinib—Sepsis—Methotrexate—colon cancer	0.000182	0.00396	CcSEcCtD
Crizotinib—MAP4K2—liver—colon cancer	0.000182	0.00239	CbGeAlD
Crizotinib—Arrhythmia—Fluorouracil—colon cancer	0.000181	0.00393	CcSEcCtD
Crizotinib—Muscular weakness—Capecitabine—colon cancer	0.000181	0.00392	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Capecitabine—colon cancer	0.000181	0.00392	CcSEcCtD
Crizotinib—YES1—renal system—colon cancer	0.00018	0.00237	CbGeAlD
Crizotinib—SRC—smooth muscle tissue—colon cancer	0.00018	0.00237	CbGeAlD
Crizotinib—MET—lymph node—colon cancer	0.00018	0.00236	CbGeAlD
Crizotinib—STK3—liver—colon cancer	0.00018	0.00236	CbGeAlD
Crizotinib—TIE1—liver—colon cancer	0.00018	0.00236	CbGeAlD
Crizotinib—RPS6KB1—lymphoid tissue—colon cancer	0.000179	0.00235	CbGeAlD
Crizotinib—STK10—renal system—colon cancer	0.000179	0.00235	CbGeAlD
Crizotinib—TAOK3—renal system—colon cancer	0.000178	0.00234	CbGeAlD
Crizotinib—FGR—lymphoid tissue—colon cancer	0.000178	0.00234	CbGeAlD
Crizotinib—AXL—lymphoid tissue—colon cancer	0.000177	0.00233	CbGeAlD
Crizotinib—RPS6KB1—digestive system—colon cancer	0.000177	0.00232	CbGeAlD
Crizotinib—PTK2B—vagina—colon cancer	0.000176	0.00232	CbGeAlD
Crizotinib—FGR—digestive system—colon cancer	0.000176	0.00231	CbGeAlD
Crizotinib—Anaemia—Vincristine—colon cancer	0.000175	0.0038	CcSEcCtD
Crizotinib—AURKA—liver—colon cancer	0.000175	0.0023	CbGeAlD
Crizotinib—RIPK2—vagina—colon cancer	0.000175	0.0023	CbGeAlD
Crizotinib—CDK7—lymph node—colon cancer	0.000174	0.00229	CbGeAlD
Crizotinib—TESK1—liver—colon cancer	0.000174	0.00228	CbGeAlD
Crizotinib—SRC—renal system—colon cancer	0.000173	0.00228	CbGeAlD
Crizotinib—MAP3K2—bone marrow—colon cancer	0.000173	0.00227	CbGeAlD
Crizotinib—TAOK2—lymph node—colon cancer	0.000173	0.00227	CbGeAlD
Crizotinib—Anaemia—Irinotecan—colon cancer	0.00017	0.0037	CcSEcCtD
Crizotinib—Hepatic failure—Methotrexate—colon cancer	0.00017	0.00368	CcSEcCtD
Crizotinib—Leukopenia—Vincristine—colon cancer	0.00017	0.00368	CcSEcCtD
Crizotinib—TBK1—bone marrow—colon cancer	0.000169	0.00223	CbGeAlD
Crizotinib—EPHA4—vagina—colon cancer	0.000169	0.00222	CbGeAlD
Crizotinib—MERTK—liver—colon cancer	0.000169	0.00222	CbGeAlD
Crizotinib—TYK2—bone marrow—colon cancer	0.000168	0.00221	CbGeAlD
Crizotinib—JAK2—lymphoid tissue—colon cancer	0.000168	0.00221	CbGeAlD
Crizotinib—EPHB4—digestive system—colon cancer	0.000167	0.0022	CbGeAlD
Crizotinib—Vision blurred—Fluorouracil—colon cancer	0.000166	0.00361	CcSEcCtD
Crizotinib—ACVR1B—lymph node—colon cancer	0.000166	0.00219	CbGeAlD
Crizotinib—EPHA3—lymph node—colon cancer	0.000166	0.00219	CbGeAlD
Crizotinib—EPHA2—lymphoid tissue—colon cancer	0.000166	0.00218	CbGeAlD
Crizotinib—IRAK1—bone marrow—colon cancer	0.000166	0.00218	CbGeAlD
Crizotinib—JAK2—digestive system—colon cancer	0.000166	0.00218	CbGeAlD
Crizotinib—Neutropenia—Capecitabine—colon cancer	0.000166	0.00359	CcSEcCtD
Crizotinib—Syncope—Irinotecan—colon cancer	0.000165	0.00359	CcSEcCtD
Crizotinib—LIMK2—liver—colon cancer	0.000165	0.00217	CbGeAlD
Crizotinib—Leukopenia—Irinotecan—colon cancer	0.000165	0.00358	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Capecitabine—colon cancer	0.000165	0.00357	CcSEcCtD
Crizotinib—NUAK2—liver—colon cancer	0.000164	0.00216	CbGeAlD
Crizotinib—EPHA2—digestive system—colon cancer	0.000164	0.00216	CbGeAlD
Crizotinib—MAP3K12—liver—colon cancer	0.000163	0.00214	CbGeAlD
Crizotinib—FLT3—liver—colon cancer	0.000163	0.00214	CbGeAlD
Crizotinib—ACVR1—liver—colon cancer	0.000163	0.00214	CbGeAlD
Crizotinib—Anaemia—Fluorouracil—colon cancer	0.000163	0.00354	CcSEcCtD
Crizotinib—RPS6KB1—bone marrow—colon cancer	0.000163	0.00214	CbGeAlD
Crizotinib—ABL1—embryo—colon cancer	0.000163	0.00214	CbGeAlD
Crizotinib—TBK1—vagina—colon cancer	0.000162	0.00213	CbGeAlD
Crizotinib—PTK2—vagina—colon cancer	0.000162	0.00213	CbGeAlD
Crizotinib—MAP4K5—lymphoid tissue—colon cancer	0.000162	0.00213	CbGeAlD
Crizotinib—TEK—lymphoid tissue—colon cancer	0.000162	0.00213	CbGeAlD
Crizotinib—Loss of consciousness—Irinotecan—colon cancer	0.000162	0.00352	CcSEcCtD
Crizotinib—FGR—bone marrow—colon cancer	0.000162	0.00213	CbGeAlD
Crizotinib—LCK—bone marrow—colon cancer	0.000162	0.00213	CbGeAlD
Crizotinib—CSF1R—smooth muscle tissue—colon cancer	0.000162	0.00212	CbGeAlD
Crizotinib—TYK2—vagina—colon cancer	0.000161	0.00212	CbGeAlD
Crizotinib—Visual disturbance—Methotrexate—colon cancer	0.000161	0.00349	CcSEcCtD
Crizotinib—Weight decreased—Capecitabine—colon cancer	0.00016	0.00348	CcSEcCtD
Crizotinib—STK35—liver—colon cancer	0.00016	0.0021	CbGeAlD
Crizotinib—Pneumonia—Capecitabine—colon cancer	0.000159	0.00345	CcSEcCtD
Crizotinib—JAK3—lymph node—colon cancer	0.000159	0.00208	CbGeAlD
Crizotinib—Leukopenia—Fluorouracil—colon cancer	0.000158	0.00343	CcSEcCtD
Crizotinib—Infestation NOS—Capecitabine—colon cancer	0.000158	0.00343	CcSEcCtD
Crizotinib—Infestation—Capecitabine—colon cancer	0.000158	0.00343	CcSEcCtD
Crizotinib—DCLK1—lymph node—colon cancer	0.000158	0.00207	CbGeAlD
Crizotinib—PLK4—lymph node—colon cancer	0.000157	0.00206	CbGeAlD
Crizotinib—RPS6KB1—vagina—colon cancer	0.000156	0.00205	CbGeAlD
Crizotinib—ABL2—liver—colon cancer	0.000156	0.00205	CbGeAlD
Crizotinib—STK4—lymph node—colon cancer	0.000156	0.00205	CbGeAlD
Crizotinib—SLK—bone marrow—colon cancer	0.000155	0.00204	CbGeAlD
Crizotinib—FGR—vagina—colon cancer	0.000155	0.00204	CbGeAlD
Crizotinib—LCK—vagina—colon cancer	0.000155	0.00204	CbGeAlD
Crizotinib—Neuropathy peripheral—Capecitabine—colon cancer	0.000155	0.00336	CcSEcCtD
Crizotinib—AXL—vagina—colon cancer	0.000155	0.00203	CbGeAlD
Crizotinib—Oedema—Vincristine—colon cancer	0.000155	0.00335	CcSEcCtD
Crizotinib—EPHB4—bone marrow—colon cancer	0.000154	0.00203	CbGeAlD
Crizotinib—BMP2K—liver—colon cancer	0.000154	0.00202	CbGeAlD
Crizotinib—Infection—Vincristine—colon cancer	0.000154	0.00333	CcSEcCtD
Crizotinib—JAK2—bone marrow—colon cancer	0.000153	0.00201	CbGeAlD
Crizotinib—Nervous system disorder—Vincristine—colon cancer	0.000152	0.00329	CcSEcCtD
Crizotinib—Oedema—Irinotecan—colon cancer	0.000151	0.00327	CcSEcCtD
Crizotinib—YES1—lymphoid tissue—colon cancer	0.00015	0.00197	CbGeAlD
Crizotinib—Infection—Irinotecan—colon cancer	0.00015	0.00324	CcSEcCtD
Crizotinib—Hepatobiliary disease—Capecitabine—colon cancer	0.000149	0.00324	CcSEcCtD
Crizotinib—SLK—vagina—colon cancer	0.000149	0.00195	CbGeAlD
Crizotinib—PTK2B—liver—colon cancer	0.000149	0.00195	CbGeAlD
Crizotinib—STK10—lymphoid tissue—colon cancer	0.000148	0.00195	CbGeAlD
Crizotinib—Shock—Irinotecan—colon cancer	0.000148	0.00321	CcSEcCtD
Crizotinib—YES1—digestive system—colon cancer	0.000148	0.00194	CbGeAlD
Crizotinib—TAOK3—lymphoid tissue—colon cancer	0.000148	0.00194	CbGeAlD
Crizotinib—EPHB4—vagina—colon cancer	0.000148	0.00194	CbGeAlD
Crizotinib—MAP4K5—bone marrow—colon cancer	0.000148	0.00194	CbGeAlD
Crizotinib—MAP3K3—bone marrow—colon cancer	0.000148	0.00194	CbGeAlD
Crizotinib—Nervous system disorder—Irinotecan—colon cancer	0.000148	0.0032	CcSEcCtD
Crizotinib—RIPK2—liver—colon cancer	0.000148	0.00194	CbGeAlD
Crizotinib—FER—lymph node—colon cancer	0.000147	0.00193	CbGeAlD
Crizotinib—ALK—lymph node—colon cancer	0.000147	0.00193	CbGeAlD
Crizotinib—JAK2—vagina—colon cancer	0.000147	0.00193	CbGeAlD
Crizotinib—STK10—digestive system—colon cancer	0.000147	0.00192	CbGeAlD
Crizotinib—TAOK3—digestive system—colon cancer	0.000146	0.00192	CbGeAlD
Crizotinib—TNK1—lymph node—colon cancer	0.000146	0.00191	CbGeAlD
Crizotinib—EPHA2—vagina—colon cancer	0.000145	0.0019	CbGeAlD
Crizotinib—Bradycardia—Capecitabine—colon cancer	0.000144	0.00313	CcSEcCtD
Crizotinib—BMPR1B—lymph node—colon cancer	0.000144	0.00189	CbGeAlD
Crizotinib—MAP4K1—lymph node—colon cancer	0.000144	0.00189	CbGeAlD
Crizotinib—Oedema—Fluorouracil—colon cancer	0.000144	0.00313	CcSEcCtD
Crizotinib—SRC—lymphoid tissue—colon cancer	0.000144	0.00189	CbGeAlD
Crizotinib—Infection—Fluorouracil—colon cancer	0.000143	0.00311	CcSEcCtD
Crizotinib—SRC—digestive system—colon cancer	0.000142	0.00187	CbGeAlD
Crizotinib—IGF1R—lymph node—colon cancer	0.000141	0.00186	CbGeAlD
Crizotinib—TNK2—lymph node—colon cancer	0.000141	0.00186	CbGeAlD
Crizotinib—MAP3K3—vagina—colon cancer	0.000141	0.00186	CbGeAlD
Crizotinib—MAP4K5—vagina—colon cancer	0.000141	0.00186	CbGeAlD
Crizotinib—Nervous system disorder—Fluorouracil—colon cancer	0.000141	0.00307	CcSEcCtD
Crizotinib—Hypoaesthesia—Capecitabine—colon cancer	0.000141	0.00306	CcSEcCtD
Crizotinib—Urinary tract disorder—Capecitabine—colon cancer	0.00014	0.00304	CcSEcCtD
Crizotinib—MAP3K2—liver—colon cancer	0.00014	0.00184	CbGeAlD
Crizotinib—Oedema peripheral—Capecitabine—colon cancer	0.00014	0.00303	CcSEcCtD
Crizotinib—MAP4K2—lymph node—colon cancer	0.00014	0.00183	CbGeAlD
Crizotinib—Urethral disorder—Capecitabine—colon cancer	0.000139	0.00302	CcSEcCtD
Crizotinib—Paraesthesia—Vincristine—colon cancer	0.000139	0.00301	CcSEcCtD
Crizotinib—TIE1—lymph node—colon cancer	0.000138	0.00181	CbGeAlD
Crizotinib—STK3—lymph node—colon cancer	0.000138	0.00181	CbGeAlD
Crizotinib—TBK1—liver—colon cancer	0.000137	0.0018	CbGeAlD
Crizotinib—PTK2—liver—colon cancer	0.000137	0.0018	CbGeAlD
Crizotinib—Visual impairment—Capecitabine—colon cancer	0.000137	0.00296	CcSEcCtD
Crizotinib—YES1—bone marrow—colon cancer	0.000136	0.00179	CbGeAlD
Crizotinib—TYK2—liver—colon cancer	0.000136	0.00179	CbGeAlD
Crizotinib—Paraesthesia—Irinotecan—colon cancer	0.000135	0.00293	CcSEcCtD
Crizotinib—EPHB6—vagina—colon cancer	0.000135	0.00177	CbGeAlD
Crizotinib—STK10—bone marrow—colon cancer	0.000135	0.00177	CbGeAlD
Crizotinib—TAOK3—bone marrow—colon cancer	0.000135	0.00177	CbGeAlD
Crizotinib—Decreased appetite—Vincristine—colon cancer	0.000134	0.00291	CcSEcCtD
Crizotinib—IRAK1—liver—colon cancer	0.000134	0.00176	CbGeAlD
Crizotinib—Dyspnoea—Irinotecan—colon cancer	0.000134	0.00291	CcSEcCtD
Crizotinib—AURKA—lymph node—colon cancer	0.000134	0.00176	CbGeAlD
Crizotinib—Gastrointestinal disorder—Vincristine—colon cancer	0.000133	0.00289	CcSEcCtD
Crizotinib—Fatigue—Vincristine—colon cancer	0.000133	0.00289	CcSEcCtD
Crizotinib—TESK1—lymph node—colon cancer	0.000133	0.00175	CbGeAlD
Crizotinib—Eye disorder—Capecitabine—colon cancer	0.000133	0.00287	CcSEcCtD
Crizotinib—Dyspepsia—Irinotecan—colon cancer	0.000132	0.00287	CcSEcCtD
Crizotinib—Constipation—Vincristine—colon cancer	0.000132	0.00287	CcSEcCtD
Crizotinib—RPS6KB1—liver—colon cancer	0.000132	0.00173	CbGeAlD
Crizotinib—Cardiac disorder—Capecitabine—colon cancer	0.000132	0.00286	CcSEcCtD
Crizotinib—LCK—liver—colon cancer	0.000131	0.00172	CbGeAlD
Crizotinib—FGR—liver—colon cancer	0.000131	0.00172	CbGeAlD
Crizotinib—Decreased appetite—Irinotecan—colon cancer	0.000131	0.00284	CcSEcCtD
Crizotinib—YES1—vagina—colon cancer	0.000131	0.00172	CbGeAlD
Crizotinib—AXL—liver—colon cancer	0.00013	0.00171	CbGeAlD
Crizotinib—Gastrointestinal disorder—Irinotecan—colon cancer	0.00013	0.00282	CcSEcCtD
Crizotinib—Fatigue—Irinotecan—colon cancer	0.00013	0.00282	CcSEcCtD
Crizotinib—Paraesthesia—Fluorouracil—colon cancer	0.000129	0.00281	CcSEcCtD
Crizotinib—STK10—vagina—colon cancer	0.000129	0.0017	CbGeAlD
Crizotinib—MERTK—lymph node—colon cancer	0.000129	0.0017	CbGeAlD
Crizotinib—CSF1R—lymphoid tissue—colon cancer	0.000129	0.0017	CbGeAlD
Crizotinib—TAOK3—vagina—colon cancer	0.000129	0.00169	CbGeAlD
Crizotinib—Constipation—Irinotecan—colon cancer	0.000129	0.00279	CcSEcCtD
Crizotinib—Dyspnoea—Fluorouracil—colon cancer	0.000129	0.00279	CcSEcCtD
Crizotinib—ABL1—smooth muscle tissue—colon cancer	0.000128	0.00168	CbGeAlD
Crizotinib—Mediastinal disorder—Capecitabine—colon cancer	0.000128	0.00277	CcSEcCtD
Crizotinib—CSF1R—digestive system—colon cancer	0.000128	0.00168	CbGeAlD
Crizotinib—Dyspepsia—Fluorouracil—colon cancer	0.000127	0.00275	CcSEcCtD
Crizotinib—Arrhythmia—Capecitabine—colon cancer	0.000127	0.00275	CcSEcCtD
Crizotinib—LIMK2—lymph node—colon cancer	0.000127	0.00166	CbGeAlD
Crizotinib—NUAK2—lymph node—colon cancer	0.000126	0.00166	CbGeAlD
Crizotinib—SLK—liver—colon cancer	0.000126	0.00165	CbGeAlD
Crizotinib—Decreased appetite—Fluorouracil—colon cancer	0.000125	0.00272	CcSEcCtD
Crizotinib—MAP3K12—lymph node—colon cancer	0.000125	0.00164	CbGeAlD
Crizotinib—ACVR1—lymph node—colon cancer	0.000125	0.00164	CbGeAlD
Crizotinib—FLT3—lymph node—colon cancer	0.000125	0.00164	CbGeAlD
Crizotinib—EPHB4—liver—colon cancer	0.000125	0.00164	CbGeAlD
Crizotinib—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000124	0.0027	CcSEcCtD
Crizotinib—JAK2—liver—colon cancer	0.000124	0.00163	CbGeAlD
Crizotinib—Malnutrition—Capecitabine—colon cancer	0.000123	0.00268	CcSEcCtD
Crizotinib—Neutropenia—Methotrexate—colon cancer	0.000123	0.00268	CcSEcCtD
Crizotinib—ABL1—renal system—colon cancer	0.000123	0.00162	CbGeAlD
Crizotinib—STK35—lymph node—colon cancer	0.000123	0.00161	CbGeAlD
Crizotinib—Upper respiratory tract infection—Methotrexate—colon cancer	0.000123	0.00266	CcSEcCtD
Crizotinib—EPHA2—liver—colon cancer	0.000122	0.00161	CbGeAlD
Crizotinib—Body temperature increased—Vincristine—colon cancer	0.000122	0.00265	CcSEcCtD
Crizotinib—Dysgeusia—Capecitabine—colon cancer	0.000121	0.00262	CcSEcCtD
Crizotinib—ABL2—lymph node—colon cancer	0.00012	0.00157	CbGeAlD
Crizotinib—MAP3K3—liver—colon cancer	0.000119	0.00157	CbGeAlD
Crizotinib—MAP4K5—liver—colon cancer	0.000119	0.00157	CbGeAlD
Crizotinib—TEK—liver—colon cancer	0.000119	0.00157	CbGeAlD
Crizotinib—Body temperature increased—Irinotecan—colon cancer	0.000119	0.00258	CcSEcCtD
Crizotinib—Pneumonia—Methotrexate—colon cancer	0.000118	0.00257	CcSEcCtD
Crizotinib—BMP2K—lymph node—colon cancer	0.000118	0.00155	CbGeAlD
Crizotinib—CSF1R—bone marrow—colon cancer	0.000118	0.00155	CbGeAlD
Crizotinib—Infestation—Methotrexate—colon cancer	0.000118	0.00255	CcSEcCtD
Crizotinib—Infestation NOS—Methotrexate—colon cancer	0.000118	0.00255	CcSEcCtD
Crizotinib—Vision blurred—Capecitabine—colon cancer	0.000116	0.00252	CcSEcCtD
Crizotinib—Anaemia—Capecitabine—colon cancer	0.000114	0.00248	CcSEcCtD
Crizotinib—PTK2B—lymph node—colon cancer	0.000114	0.0015	CbGeAlD
Crizotinib—Body temperature increased—Fluorouracil—colon cancer	0.000114	0.00247	CcSEcCtD
Crizotinib—RIPK2—lymph node—colon cancer	0.000113	0.00149	CbGeAlD
Crizotinib—CSF1R—vagina—colon cancer	0.000113	0.00148	CbGeAlD
Crizotinib—Hepatobiliary disease—Methotrexate—colon cancer	0.000111	0.00241	CcSEcCtD
Crizotinib—Asthenia—Vincristine—colon cancer	0.000111	0.00241	CcSEcCtD
Crizotinib—Syncope—Capecitabine—colon cancer	0.000111	0.0024	CcSEcCtD
Crizotinib—Leukopenia—Capecitabine—colon cancer	0.00011	0.0024	CcSEcCtD
Crizotinib—YES1—liver—colon cancer	0.00011	0.00145	CbGeAlD
Crizotinib—EPHA4—lymph node—colon cancer	0.000109	0.00144	CbGeAlD
Crizotinib—STK10—liver—colon cancer	0.000109	0.00143	CbGeAlD
Crizotinib—TAOK3—liver—colon cancer	0.000109	0.00143	CbGeAlD
Crizotinib—Loss of consciousness—Capecitabine—colon cancer	0.000108	0.00235	CcSEcCtD
Crizotinib—Asthenia—Irinotecan—colon cancer	0.000108	0.00234	CcSEcCtD
Crizotinib—MAP3K2—lymph node—colon cancer	0.000107	0.00141	CbGeAlD
Crizotinib—SRC—liver—colon cancer	0.000106	0.00139	CbGeAlD
Crizotinib—Diarrhoea—Vincristine—colon cancer	0.000106	0.00229	CcSEcCtD
Crizotinib—TBK1—lymph node—colon cancer	0.000105	0.00138	CbGeAlD
Crizotinib—PTK2—lymph node—colon cancer	0.000105	0.00138	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000104	0.00226	CcSEcCtD
Crizotinib—TYK2—lymph node—colon cancer	0.000104	0.00137	CbGeAlD
Crizotinib—Urinary tract disorder—Methotrexate—colon cancer	0.000104	0.00226	CcSEcCtD
Crizotinib—Urethral disorder—Methotrexate—colon cancer	0.000103	0.00224	CcSEcCtD
Crizotinib—Diarrhoea—Irinotecan—colon cancer	0.000103	0.00223	CcSEcCtD
Crizotinib—IRAK1—lymph node—colon cancer	0.000103	0.00135	CbGeAlD
Crizotinib—ABL1—lymphoid tissue—colon cancer	0.000102	0.00134	CbGeAlD
Crizotinib—Dizziness—Vincristine—colon cancer	0.000102	0.00222	CcSEcCtD
Crizotinib—Visual impairment—Methotrexate—colon cancer	0.000102	0.00221	CcSEcCtD
Crizotinib—RPS6KB1—lymph node—colon cancer	0.000101	0.00133	CbGeAlD
Crizotinib—ABL1—digestive system—colon cancer	0.000101	0.00133	CbGeAlD
Crizotinib—Oedema—Capecitabine—colon cancer	0.000101	0.00219	CcSEcCtD
Crizotinib—FGR—lymph node—colon cancer	0.0001	0.00132	CbGeAlD
Crizotinib—LCK—lymph node—colon cancer	0.0001	0.00132	CbGeAlD
Crizotinib—Infection—Capecitabine—colon cancer	0.0001	0.00217	CcSEcCtD
Crizotinib—AXL—lymph node—colon cancer	0.0001	0.00131	CbGeAlD
Crizotinib—Dizziness—Irinotecan—colon cancer	9.95e-05	0.00216	CcSEcCtD
Crizotinib—Shock—Capecitabine—colon cancer	9.91e-05	0.00215	CcSEcCtD
Crizotinib—Nervous system disorder—Capecitabine—colon cancer	9.88e-05	0.00214	CcSEcCtD
Crizotinib—Eye disorder—Methotrexate—colon cancer	9.86e-05	0.00214	CcSEcCtD
Crizotinib—Diarrhoea—Fluorouracil—colon cancer	9.86e-05	0.00214	CcSEcCtD
Crizotinib—Vomiting—Vincristine—colon cancer	9.83e-05	0.00213	CcSEcCtD
Crizotinib—Cardiac disorder—Methotrexate—colon cancer	9.8e-05	0.00213	CcSEcCtD
Crizotinib—Skin disorder—Capecitabine—colon cancer	9.78e-05	0.00212	CcSEcCtD
Crizotinib—Rash—Vincristine—colon cancer	9.74e-05	0.00211	CcSEcCtD
Crizotinib—Dermatitis—Vincristine—colon cancer	9.74e-05	0.00211	CcSEcCtD
Crizotinib—SLK—lymph node—colon cancer	9.63e-05	0.00126	CbGeAlD
Crizotinib—Vomiting—Irinotecan—colon cancer	9.57e-05	0.00208	CcSEcCtD
Crizotinib—EPHB4—lymph node—colon cancer	9.56e-05	0.00126	CbGeAlD
Crizotinib—Dizziness—Fluorouracil—colon cancer	9.53e-05	0.00207	CcSEcCtD
Crizotinib—CSF1R—liver—colon cancer	9.52e-05	0.00125	CbGeAlD
Crizotinib—Mediastinal disorder—Methotrexate—colon cancer	9.51e-05	0.00206	CcSEcCtD
Crizotinib—JAK2—lymph node—colon cancer	9.49e-05	0.00125	CbGeAlD
Crizotinib—Rash—Irinotecan—colon cancer	9.49e-05	0.00206	CcSEcCtD
Crizotinib—Dermatitis—Irinotecan—colon cancer	9.48e-05	0.00206	CcSEcCtD
Crizotinib—EPHA2—lymph node—colon cancer	9.38e-05	0.00123	CbGeAlD
Crizotinib—ABL1—bone marrow—colon cancer	9.31e-05	0.00122	CbGeAlD
Crizotinib—Malnutrition—Methotrexate—colon cancer	9.19e-05	0.00199	CcSEcCtD
Crizotinib—Nausea—Vincristine—colon cancer	9.18e-05	0.00199	CcSEcCtD
Crizotinib—Vomiting—Fluorouracil—colon cancer	9.17e-05	0.00199	CcSEcCtD
Crizotinib—MAP4K5—lymph node—colon cancer	9.15e-05	0.0012	CbGeAlD
Crizotinib—MAP3K3—lymph node—colon cancer	9.15e-05	0.0012	CbGeAlD
Crizotinib—TEK—lymph node—colon cancer	9.15e-05	0.0012	CbGeAlD
Crizotinib—Rash—Fluorouracil—colon cancer	9.09e-05	0.00197	CcSEcCtD
Crizotinib—Dermatitis—Fluorouracil—colon cancer	9.08e-05	0.00197	CcSEcCtD
Crizotinib—Paraesthesia—Capecitabine—colon cancer	9.05e-05	0.00196	CcSEcCtD
Crizotinib—Dysgeusia—Methotrexate—colon cancer	9e-05	0.00195	CcSEcCtD
Crizotinib—Dyspnoea—Capecitabine—colon cancer	8.98e-05	0.00195	CcSEcCtD
Crizotinib—Nausea—Irinotecan—colon cancer	8.94e-05	0.00194	CcSEcCtD
Crizotinib—ABL1—vagina—colon cancer	8.92e-05	0.00117	CbGeAlD
Crizotinib—Dyspepsia—Capecitabine—colon cancer	8.87e-05	0.00192	CcSEcCtD
Crizotinib—Decreased appetite—Capecitabine—colon cancer	8.76e-05	0.0019	CcSEcCtD
Crizotinib—EPHB6—lymph node—colon cancer	8.74e-05	0.00115	CbGeAlD
Crizotinib—Gastrointestinal disorder—Capecitabine—colon cancer	8.7e-05	0.00189	CcSEcCtD
Crizotinib—Fatigue—Capecitabine—colon cancer	8.68e-05	0.00188	CcSEcCtD
Crizotinib—Vision blurred—Methotrexate—colon cancer	8.66e-05	0.00188	CcSEcCtD
Crizotinib—Constipation—Capecitabine—colon cancer	8.61e-05	0.00187	CcSEcCtD
Crizotinib—Nausea—Fluorouracil—colon cancer	8.56e-05	0.00186	CcSEcCtD
Crizotinib—Anaemia—Methotrexate—colon cancer	8.49e-05	0.00184	CcSEcCtD
Crizotinib—ABCB1—blood vessel—colon cancer	8.48e-05	0.00111	CbGeAlD
Crizotinib—YES1—lymph node—colon cancer	8.45e-05	0.00111	CbGeAlD
Crizotinib—STK10—lymph node—colon cancer	8.37e-05	0.0011	CbGeAlD
Crizotinib—TAOK3—lymph node—colon cancer	8.34e-05	0.0011	CbGeAlD
Crizotinib—Leukopenia—Methotrexate—colon cancer	8.22e-05	0.00178	CcSEcCtD
Crizotinib—SRC—lymph node—colon cancer	8.13e-05	0.00107	CbGeAlD
Crizotinib—Body temperature increased—Capecitabine—colon cancer	7.96e-05	0.00173	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	7.77e-05	0.00169	CcSEcCtD
Crizotinib—ABL1—liver—colon cancer	7.52e-05	0.000988	CbGeAlD
Crizotinib—Infection—Methotrexate—colon cancer	7.45e-05	0.00162	CcSEcCtD
Crizotinib—Nervous system disorder—Methotrexate—colon cancer	7.35e-05	0.0016	CcSEcCtD
Crizotinib—CSF1R—lymph node—colon cancer	7.3e-05	0.000958	CbGeAlD
Crizotinib—Skin disorder—Methotrexate—colon cancer	7.28e-05	0.00158	CcSEcCtD
Crizotinib—Asthenia—Capecitabine—colon cancer	7.23e-05	0.00157	CcSEcCtD
Crizotinib—CYP3A5—renal system—colon cancer	7.21e-05	0.000946	CbGeAlD
Crizotinib—Diarrhoea—Capecitabine—colon cancer	6.89e-05	0.0015	CcSEcCtD
Crizotinib—Paraesthesia—Methotrexate—colon cancer	6.73e-05	0.00146	CcSEcCtD
Crizotinib—Dyspnoea—Methotrexate—colon cancer	6.69e-05	0.00145	CcSEcCtD
Crizotinib—Dizziness—Capecitabine—colon cancer	6.66e-05	0.00145	CcSEcCtD
Crizotinib—Dyspepsia—Methotrexate—colon cancer	6.6e-05	0.00143	CcSEcCtD
Crizotinib—Decreased appetite—Methotrexate—colon cancer	6.52e-05	0.00141	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Methotrexate—colon cancer	6.47e-05	0.0014	CcSEcCtD
Crizotinib—Fatigue—Methotrexate—colon cancer	6.47e-05	0.0014	CcSEcCtD
Crizotinib—Vomiting—Capecitabine—colon cancer	6.4e-05	0.00139	CcSEcCtD
Crizotinib—Rash—Capecitabine—colon cancer	6.35e-05	0.00138	CcSEcCtD
Crizotinib—Dermatitis—Capecitabine—colon cancer	6.35e-05	0.00138	CcSEcCtD
Crizotinib—Nausea—Capecitabine—colon cancer	5.98e-05	0.0013	CcSEcCtD
Crizotinib—Body temperature increased—Methotrexate—colon cancer	5.93e-05	0.00129	CcSEcCtD
Crizotinib—CYP3A5—digestive system—colon cancer	5.91e-05	0.000776	CbGeAlD
Crizotinib—ABL1—lymph node—colon cancer	5.77e-05	0.000757	CbGeAlD
Crizotinib—CYP3A4—renal system—colon cancer	5.41e-05	0.00071	CbGeAlD
Crizotinib—Asthenia—Methotrexate—colon cancer	5.38e-05	0.00117	CcSEcCtD
Crizotinib—CYP3A5—vagina—colon cancer	5.22e-05	0.000685	CbGeAlD
Crizotinib—Diarrhoea—Methotrexate—colon cancer	5.13e-05	0.00111	CcSEcCtD
Crizotinib—ABCB1—embryo—colon cancer	5.06e-05	0.000664	CbGeAlD
Crizotinib—Dizziness—Methotrexate—colon cancer	4.96e-05	0.00108	CcSEcCtD
Crizotinib—Vomiting—Methotrexate—colon cancer	4.77e-05	0.00103	CcSEcCtD
Crizotinib—Rash—Methotrexate—colon cancer	4.73e-05	0.00103	CcSEcCtD
Crizotinib—Dermatitis—Methotrexate—colon cancer	4.72e-05	0.00102	CcSEcCtD
Crizotinib—Nausea—Methotrexate—colon cancer	4.45e-05	0.000966	CcSEcCtD
Crizotinib—CYP3A4—digestive system—colon cancer	4.44e-05	0.000582	CbGeAlD
Crizotinib—CYP3A5—liver—colon cancer	4.4e-05	0.000578	CbGeAlD
Crizotinib—ABCB1—epithelium—colon cancer	4.13e-05	0.000542	CbGeAlD
Crizotinib—ABCB1—renal system—colon cancer	3.83e-05	0.000503	CbGeAlD
Crizotinib—CYP3A4—liver—colon cancer	3.3e-05	0.000434	CbGeAlD
Crizotinib—ABCB1—lymphoid tissue—colon cancer	3.18e-05	0.000417	CbGeAlD
Crizotinib—ABCB1—digestive system—colon cancer	3.14e-05	0.000412	CbGeAlD
Crizotinib—ABCB1—bone marrow—colon cancer	2.89e-05	0.00038	CbGeAlD
Crizotinib—ABCB1—vagina—colon cancer	2.77e-05	0.000364	CbGeAlD
Crizotinib—ABCB1—liver—colon cancer	2.34e-05	0.000307	CbGeAlD
Crizotinib—ABCB1—lymph node—colon cancer	1.79e-05	0.000236	CbGeAlD
Crizotinib—RPS6KB1—Signaling Pathways—EGFR—colon cancer	1.34e-06	1.19e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—EGFR—colon cancer	1.34e-06	1.19e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HRAS—colon cancer	1.33e-06	1.19e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCND1—colon cancer	1.33e-06	1.19e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EP300—colon cancer	1.33e-06	1.19e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CDKN1A—colon cancer	1.32e-06	1.18e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—EP300—colon cancer	1.32e-06	1.18e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CDKN1A—colon cancer	1.32e-06	1.18e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—HRAS—colon cancer	1.32e-06	1.18e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CTNNB1—colon cancer	1.31e-06	1.17e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—SRC—colon cancer	1.31e-06	1.17e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—HRAS—colon cancer	1.3e-06	1.17e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—AKT1—colon cancer	1.3e-06	1.17e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—EGFR—colon cancer	1.3e-06	1.17e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—KRAS—colon cancer	1.3e-06	1.16e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—AKT1—colon cancer	1.3e-06	1.16e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EGFR—colon cancer	1.3e-06	1.16e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HRAS—colon cancer	1.29e-06	1.16e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—PIK3CA—colon cancer	1.29e-06	1.15e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—SRC—colon cancer	1.29e-06	1.15e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—SRC—colon cancer	1.29e-06	1.15e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—APC—colon cancer	1.28e-06	1.15e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CDKN1A—colon cancer	1.28e-06	1.15e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—AKT1—colon cancer	1.28e-06	1.14e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—PIK3CA—colon cancer	1.28e-06	1.14e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—colon cancer	1.27e-06	1.14e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—PIK3CA—colon cancer	1.27e-06	1.13e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—KRAS—colon cancer	1.26e-06	1.13e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—KRAS—colon cancer	1.26e-06	1.13e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NRAS—colon cancer	1.26e-06	1.13e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EP300—colon cancer	1.26e-06	1.12e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—AKT1—colon cancer	1.26e-06	1.12e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—colon cancer	1.26e-06	1.12e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—EP300—colon cancer	1.25e-06	1.12e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HRAS—colon cancer	1.25e-06	1.12e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—PIK3CA—colon cancer	1.25e-06	1.12e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—AKT1—colon cancer	1.25e-06	1.12e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—AKT1—colon cancer	1.25e-06	1.12e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CTNNB1—colon cancer	1.25e-06	1.11e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NRAS—colon cancer	1.24e-06	1.11e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—AKT1—colon cancer	1.24e-06	1.11e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGFR3—colon cancer	1.24e-06	1.11e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NRAS—colon cancer	1.24e-06	1.11e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—colon cancer	1.23e-06	1.1e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—KRAS—colon cancer	1.23e-06	1.1e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—colon cancer	1.23e-06	1.1e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—KRAS—colon cancer	1.23e-06	1.1e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—SRC—colon cancer	1.22e-06	1.09e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EP300—colon cancer	1.22e-06	1.09e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EGFR—colon cancer	1.22e-06	1.09e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—SRC—colon cancer	1.22e-06	1.09e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CDKN1A—colon cancer	1.22e-06	1.09e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—colon cancer	1.21e-06	1.08e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—BRAF—colon cancer	1.21e-06	1.08e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—PIK3CA—colon cancer	1.2e-06	1.07e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CTNNB1—colon cancer	1.19e-06	1.07e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—HRAS—colon cancer	1.19e-06	1.07e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—colon cancer	1.19e-06	1.07e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—SRC—colon cancer	1.19e-06	1.06e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NRAS—colon cancer	1.18e-06	1.05e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—AKT1—colon cancer	1.18e-06	1.05e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HRAS—colon cancer	1.17e-06	1.05e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—NRAS—colon cancer	1.17e-06	1.05e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MYC—colon cancer	1.17e-06	1.05e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TGFB1—colon cancer	1.17e-06	1.05e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CDKN1A—colon cancer	1.17e-06	1.04e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—AKT1—colon cancer	1.16e-06	1.04e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—PIK3CA—colon cancer	1.16e-06	1.04e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—PIK3CA—colon cancer	1.16e-06	1.04e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—EP300—colon cancer	1.16e-06	1.04e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—colon cancer	1.16e-06	1.03e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—colon cancer	1.16e-06	1.03e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HRAS—colon cancer	1.16e-06	1.03e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MYC—colon cancer	1.16e-06	1.03e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TGFB1—colon cancer	1.15e-06	1.03e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KRAS—colon cancer	1.15e-06	1.03e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—MYC—colon cancer	1.15e-06	1.03e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—AKT1—colon cancer	1.15e-06	1.03e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—TGFB1—colon cancer	1.15e-06	1.03e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EGFR—colon cancer	1.15e-06	1.03e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NRAS—colon cancer	1.14e-06	1.02e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—AKT1—colon cancer	1.14e-06	1.02e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—APC—colon cancer	1.14e-06	1.02e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—PIK3CA—colon cancer	1.13e-06	1.01e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EGFR—colon cancer	1.13e-06	1.01e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—EGFR—colon cancer	1.13e-06	1.01e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—PIK3CA—colon cancer	1.13e-06	1.01e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—SRC—colon cancer	1.13e-06	1.01e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—colon cancer	1.12e-06	1e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—EP300—colon cancer	1.11e-06	9.93e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HRAS—colon cancer	1.11e-06	9.89e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—AKT1—colon cancer	1.11e-06	9.89e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CASP3—colon cancer	1.1e-06	9.87e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CTNNB1—colon cancer	1.1e-06	9.86e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—colon cancer	1.1e-06	9.8e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TYMS—colon cancer	1.1e-06	9.8e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TGFB1—colon cancer	1.09e-06	9.78e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—NRAS—colon cancer	1.08e-06	9.68e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—colon cancer	1.08e-06	9.68e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1A—colon cancer	1.08e-06	9.63e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCND1—colon cancer	1.07e-06	9.61e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—colon cancer	1.07e-06	9.59e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—colon cancer	1.07e-06	9.59e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—colon cancer	1.07e-06	9.59e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—colon cancer	1.07e-06	9.56e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—BRAF—colon cancer	1.07e-06	9.55e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—colon cancer	1.07e-06	9.55e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—colon cancer	1.06e-06	9.52e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—colon cancer	1.06e-06	9.52e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CTNNB1—colon cancer	1.06e-06	9.51e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFB1—colon cancer	1.06e-06	9.49e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PIK3CA—colon cancer	1.06e-06	9.47e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—colon cancer	1.05e-06	9.42e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—colon cancer	1.05e-06	9.36e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—colon cancer	1.04e-06	9.32e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—colon cancer	1.04e-06	9.32e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—colon cancer	1.04e-06	9.31e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1A—colon cancer	1.04e-06	9.29e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—NRAS—colon cancer	1.04e-06	9.29e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—colon cancer	1.04e-06	9.26e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP3—colon cancer	1.03e-06	9.24e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PPARG—colon cancer	1.03e-06	9.2e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EP300—colon cancer	1.03e-06	9.16e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—colon cancer	1.02e-06	9.13e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—colon cancer	1.01e-06	9.06e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—colon cancer	1.01e-06	9.03e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—colon cancer	1.01e-06	9.02e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFB1—colon cancer	1.01e-06	9e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—colon cancer	1.01e-06	8.99e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CTNNB1—colon cancer	9.96e-07	8.9e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PIK3CA—colon cancer	9.95e-07	8.9e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EP300—colon cancer	9.89e-07	8.84e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—colon cancer	9.87e-07	8.82e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—colon cancer	9.84e-07	8.79e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PIK3CA—colon cancer	9.82e-07	8.77e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—colon cancer	9.8e-07	8.76e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PIK3CA—colon cancer	9.78e-07	8.74e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—colon cancer	9.77e-07	8.74e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1A—colon cancer	9.73e-07	8.7e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—colon cancer	9.63e-07	8.61e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SRC—colon cancer	9.62e-07	8.6e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—NRAS—colon cancer	9.59e-07	8.57e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—colon cancer	9.5e-07	8.49e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—colon cancer	9.48e-07	8.47e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—colon cancer	9.47e-07	8.47e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—colon cancer	9.46e-07	8.46e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—colon cancer	9.37e-07	8.38e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—colon cancer	9.32e-07	8.33e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PIK3CA—colon cancer	9.31e-07	8.32e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—PIK3CA—colon cancer	9.28e-07	8.29e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EP300—colon cancer	9.26e-07	8.28e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NRAS—colon cancer	9.26e-07	8.27e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—colon cancer	9.25e-07	8.27e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—colon cancer	9.21e-07	8.23e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—colon cancer	9.2e-07	8.23e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—colon cancer	9.08e-07	8.12e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP3—colon cancer	9.05e-07	8.09e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—colon cancer	9.05e-07	8.09e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PIK3CA—colon cancer	9.04e-07	8.08e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—colon cancer	9.01e-07	8.05e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SRC—colon cancer	9e-07	8.05e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—colon cancer	8.94e-07	7.99e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—colon cancer	8.93e-07	7.99e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFB1—colon cancer	8.91e-07	7.97e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—colon cancer	8.81e-07	7.87e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—colon cancer	8.77e-07	7.84e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—colon cancer	8.74e-07	7.81e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—colon cancer	8.74e-07	7.81e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CTNNB1—colon cancer	8.72e-07	7.8e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NRAS—colon cancer	8.66e-07	7.74e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—colon cancer	8.65e-07	7.74e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—colon cancer	8.62e-07	7.71e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—colon cancer	8.61e-07	7.7e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFB1—colon cancer	8.6e-07	7.69e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—colon cancer	8.58e-07	7.67e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PIK3CA—colon cancer	8.57e-07	7.66e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1A—colon cancer	8.52e-07	7.62e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—colon cancer	8.43e-07	7.54e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—colon cancer	8.36e-07	7.47e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—colon cancer	8.25e-07	7.38e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PIK3CA—colon cancer	8.21e-07	7.34e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—colon cancer	8.13e-07	7.27e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EP300—colon cancer	8.11e-07	7.25e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—colon cancer	8.09e-07	7.23e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—colon cancer	8.07e-07	7.21e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFB1—colon cancer	8.05e-07	7.19e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—colon cancer	8.02e-07	7.17e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP3—colon cancer	8.01e-07	7.16e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—colon cancer	7.99e-07	7.14e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—colon cancer	7.97e-07	7.12e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—colon cancer	7.93e-07	7.08e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—colon cancer	7.89e-07	7.05e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SRC—colon cancer	7.89e-07	7.05e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—colon cancer	7.8e-07	6.97e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARG—colon cancer	7.76e-07	6.94e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CTNNB1—colon cancer	7.72e-07	6.9e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—colon cancer	7.68e-07	6.87e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—colon cancer	7.6e-07	6.8e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—colon cancer	7.6e-07	6.79e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NRAS—colon cancer	7.59e-07	6.78e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PIK3CA—colon cancer	7.58e-07	6.78e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—colon cancer	7.58e-07	6.78e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1A—colon cancer	7.54e-07	6.74e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—colon cancer	7.45e-07	6.66e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—colon cancer	7.38e-07	6.6e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CA—colon cancer	7.32e-07	6.54e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EP300—colon cancer	7.18e-07	6.42e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—colon cancer	7.08e-07	6.33e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—colon cancer	7.07e-07	6.32e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFB1—colon cancer	7.05e-07	6.3e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—colon cancer	7.02e-07	6.27e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—colon cancer	7e-07	6.26e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—colon cancer	6.91e-07	6.18e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ABCB1—colon cancer	6.88e-07	6.15e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CA—colon cancer	6.85e-07	6.12e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—colon cancer	6.8e-07	6.08e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—colon cancer	6.77e-07	6.05e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TYMS—colon cancer	6.75e-07	6.04e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—EP300—colon cancer	6.73e-07	6.02e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NRAS—colon cancer	6.72e-07	6e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—colon cancer	6.71e-07	6e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—colon cancer	6.63e-07	5.92e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—colon cancer	6.53e-07	5.84e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—colon cancer	6.34e-07	5.66e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—colon cancer	6.26e-07	5.59e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFB1—colon cancer	6.24e-07	5.58e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—colon cancer	6.2e-07	5.54e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—colon cancer	6.12e-07	5.47e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—colon cancer	6.11e-07	5.46e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CA—colon cancer	6e-07	5.36e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—colon cancer	5.98e-07	5.34e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—colon cancer	5.8e-07	5.19e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—colon cancer	5.78e-07	5.17e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—colon cancer	5.6e-07	5e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—colon cancer	5.55e-07	4.96e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CA—colon cancer	5.31e-07	4.75e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—colon cancer	5.14e-07	4.59e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—EP300—colon cancer	5.08e-07	4.54e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CA—colon cancer	4.98e-07	4.45e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—colon cancer	4.91e-07	4.39e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—colon cancer	4.9e-07	4.38e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARG—colon cancer	4.78e-07	4.28e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—colon cancer	4.34e-07	3.88e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—colon cancer	4.07e-07	3.64e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—colon cancer	3.76e-07	3.36e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CA—colon cancer	3.76e-07	3.36e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—EP300—colon cancer	3.13e-07	2.8e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—colon cancer	3.07e-07	2.74e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CA—colon cancer	2.32e-07	2.07e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—colon cancer	1.89e-07	1.69e-06	CbGpPWpGaD
